A detailed history of China Universal Asset Management Co., Ltd. transactions in Ascendis Pharma A/S stock. As of the latest transaction made, China Universal Asset Management Co., Ltd. holds 11,020 shares of ASND stock, worth $1.48 Million. This represents 0.22% of its overall portfolio holdings.

Number of Shares
11,020
Previous 11,020 -0.0%
Holding current value
$1.48 Million
Previous $1.67 Million 0.06%
% of portfolio
0.22%
Previous 0.21%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 29, 2024

BUY
$123.45 - $159.4 $541,328 - $698,969
4,385 Added 66.09%
11,020 $1.67 Million
Q4 2023

May 21, 2024

SELL
$86.1 - $127.36 $377,548 - $558,473
-4,385 Reduced 39.79%
6,635 $835,000
Q4 2023

Jan 23, 2024

BUY
$86.1 - $127.36 $445,395 - $658,833
5,173 Added 353.83%
6,635 $836,000
Q3 2023

May 21, 2024

BUY
$86.5 - $103.97 $61,761 - $74,234
714 Added 95.45%
1,462 $136,000
Q3 2023

Oct 30, 2023

BUY
$86.5 - $103.97 $61,761 - $74,234
714 Added 95.45%
1,462 $137,000
Q2 2023

May 21, 2024

SELL
$69.96 - $97.84 $1,609 - $2,250
-23 Reduced 2.98%
748 $66,000
Q2 2023

Jul 27, 2023

SELL
$69.96 - $97.84 $1,609 - $2,250
-23 Reduced 2.98%
748 $67,000
Q1 2023

May 21, 2024

BUY
$104.9 - $126.78 $21,399 - $25,863
204 Added 35.98%
771 $82,000
Q1 2023

Apr 27, 2023

BUY
$104.9 - $126.78 $21,399 - $25,863
204 Added 35.98%
771 $83,000
Q4 2022

May 21, 2024

SELL
$99.42 - $131.97 $1.04 Million - $1.38 Million
-10,453 Reduced 94.85%
567 $69,000
Q4 2022

Jan 31, 2023

BUY
$99.42 - $131.97 $4,672 - $6,202
47 Added 9.04%
567 $69,000
Q3 2022

Oct 21, 2022

BUY
$84.03 - $110.23 $43,695 - $57,319
520 New
520 $54,000

Others Institutions Holding ASND

About Ascendis Pharma A/S


  • Ticker ASND
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,810,200
  • Market Cap $7.49B
  • Description
  • Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...
More about ASND
Track This Portfolio

Track China Universal Asset Management Co., Ltd. Portfolio

Follow China Universal Asset Management Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of China Universal Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on China Universal Asset Management Co., Ltd. with notifications on news.